2026-05-10T05:26:49Z https://www.peertechzpublications.org/oai-pmh

oai:www.peertechzpublications.org:10.17352/2581-4265.000056 2021-12-03 PTZ.ANPC:VOL7

Can newborn screening be cost benefit procedure if preventing serious complications of cystic fibrosis? Mirna Šubat-Dežulović Gordana Pelčić Ana Valković Sanja Flajšman-Raspor Goran PelčićAnamarija Gjuran Coha<p>Cystic Fibrosis (CF) is a common inherited disease with reported mean prevalence of 0.737/10,000 in 27 EU countries (Farrell J Cyst Fibros. 2008). Still, many EU countries have not implemented CF in the Newborn Screening (NBS) programme, including our country.&nbsp; We report the case of a 7-month-old boy whose presenting signs of CF were life-threatening neurological symptoms caused by severe metabolic alkalosis and hypoelectrolytemia. By presenting this case, we argue hoping to persuade the authorities in any country that the available newborn screening for CF is the cost benefit procedure in preventing life treating consequences with the obvious impact on the long-term prognosis of this chronic disease.&nbsp;</p> Archives of Nursing Practice and Care - Peertechz Publications 2021-12-03 Case Report https://doi.org/10.17352/2581-4265.000056 en Copyright © Mirna Šubat-Dežulović et al.